Manufacturer
BAXTER ONCOLOGY GMBH
 
Contents
Cetrorelix acetate
 
Indication
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation followed by oocyte pick-up & assisted reproductive techniques.
 
Instruction
SC Administer once daily into lower abdominal wall at 24-hr intervals, in the morning or evening. Administration in the morning: Commence on day 5 or 6 of ovarian stimulation (approx 96-120 hr after start of ovarian stimulation) w/ urinary or recombinant gonadotropins. Continue throughout the gonadotropin treatment period including the day of ovulation induction. Administration in the evening: Commence on day 5 of ovarian stimulation (approx 96-108 hr after start of ovarian stimulation) w/ urinary or recombinant gonadotropins. Continue throughout the gonadotropin treatment period until the evening prior to the day of ovulation induction.
 
Drug interaction
In vitro investigations have shown that interactions are unlikely with medicinal products that are metabolised by cytochrome P-450 or glucuronised or conjugated in some other way. However, although there has been no evidence of drug interactions, especially with commonly used medicinal products, gonadotropins or products that may induce histamine release in susceptible individuals, the possibility of interactions cannot be totally excluded.
Incompatibilities: Cetrotide must not be mixed with other medicinal products except the solvent provided.